clinical trials

The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than a million hospitalizations each year.

A new drug candidate could become a first-in-class medication, after impressive results in a mid-stage clinical trial for drug-resistant epilepsy. It now moves to Phase 3 trials, raising hope for people who suffer seizures despite being on medication.

In a landmark move, the FDA has given biotech company eGenesis the go-ahead to conduct a wider trial of pig-to-human kidney transplants, marking a significant step forward in addressing the critical organ shortage now facing thousands of Americans.

A new drug that significantly lowers "stubborn" blood pressure is on the horizon, following the results of its Phase III clinical trial. The drug, called baxdrostat, is being hailed as the most promising advance in hypertension management in decades.

This year a clinical trial will test a drug combination designed to bring lasting relief for people with panic disorder – a condition that can upend daily life and be notoriously difficult to treat. No new medications have been approved since 2003.

People with fibromyalgia will soon have access to a new drug that treats the chronic pain condition's most elusive trigger: Poor sleep. Tonmya, a non-opioid under-the-tongue tablet, is the first FDA-approved drug for fibromyalgia in more than 15 years.

A novel drug, evenamide, quieted overactive brain circuits in an animal model of schizophrenia, improving memory, social interaction, and dopamine balance, offering hope for tackling symptoms that current antipsychotics can’t touch.

We're closing in on an oral male pill that doesn't change hormones or libido, is fully reversible and has no side effects. YCT-529, a new kind of contraceptive mechanism, has also sparked debate about disparities in men's and women's health research.

Scientists have developed a non-opioid oral painkiller known as ADRIANA, the world's first α2B-adrenoceptor antagonist – which hasn't been targeted for analgesics before. It's provided powerful pain relief without sedation or risk of addiction.

It looks like we'll see oral GLP-1 drugs on the market by 2026, with Eli Lilly reporting impressive results from a large, robust 72-week trial that saw obese patients lose an average of 27.3 lb, or 12.4% of their body weight, with a once-daily pill.

What if you could inject a drug into a "problem area" – like the abdomen – and have it safely and rapidly kill off fat cells? We could be within 12 months of this reality, as the world's first safe, targeted fat-loss jab enters Phase 3 trials.

From St John’s wort to vitamin D, the range of over-the-counter supplements for mental health wellbeing continues to grow. Now, scientists have looked at 64 products reviewed in hundreds of studies to shed light on how useful they are for depression.